Background
Brian Rifkin
Attacking the Origin of IgAN: ORIGIN3 and ...

This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Attacking the Origin of IgAN: ORIGIN3 and Atacicept
news
swapnil hiremath
Kidney Week in Houston: Day 3

Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.

Kidney Week in Houston: Day 3
Background, news
swapnil hiremath
Kidney Week in Houston: Day 2

in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more

Kidney Week in Houston: Day 2
Background, news
swapnil hiremath
Kidney Week in Houston: Day 1

in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

Kidney Week in Houston: Day 1
Background
Cristina Adriana Popa
2025 IgAN KDIGO guidelines: fresh out of ...

This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully

esrd

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?